In MSI-high cases, the use of NSAIDs was associated with over a 70% risk reduction in KRAS- or BRAF-WT tumours, but no reductions were found in KRAS- or BRAF-mutant cases [39]. The gene discussed is KRAS; the disease is neoplasm.